The space will be used to construct a new Radiopharmaceutical Contract Manufacturing Center of Excellence, SOFIE, said.
“The Center of Excellence is a crucial piece to our growth strategy, specifically around providing access for clinical trials of our recently acquired IP,” Philipp Czernin, chief revenue officer, SOFIE, said.
The facility, which is located adjacent to its existing 10,000-square-foot diagnostic manufacturing site in Totowa, will manufacturing multiple therapeutic radiopharmaceuticals at a larger scale than its previous Somerset facility, it said. It will be entirely self-sufficient, SOFIE said, containing quality control, research and development, and microbiology laboratories.
“Together, the two Totowa, N.J. sites will total 30,000 square feet of premier radiopharmaceutical manufacturing space to support the needs of SOFIE’s pharma partners, as well forward looking for in-house theranostics. We’re excited to more fully support the burgeoning field of radioisotope-based therapeutics and diagnostics with this new facility,” Melissa Moore, chief technology officer, SOFIE, said.
Financial terms were not disclosed.